Skip Navigation



Human Molecular Genetics Advance Access published online on January 13, 2005

Human Molecular Genetics, doi:10.1093/hmg/ddi053
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
14/5/565    most recent
ddi053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Björkqvist, M.
Right arrow Articles by Mulder, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Björkqvist, M.
Right arrow Articles by Mulder, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics © Oxford University Press 2005; all rights reserved

Article

The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis

Maria Björkqvist 1*, Malin Fex 2, Erik Renström 3, Nils Wierup 4, Åsa Petersén 5, Joana Gil 5, Karl Bacos 2, Natalija Popovic 5, Jia-Yi Li 5, Frank Sundler 4, Patrik Brundin 5, and Hindrik Mulder 2

1 Department of Cell and Molecular Biology, Section for Molecular Signaling, Lund University, BMC C11, SE-221 84 Lund; Sweden
2 Department of Cell and Molecular Biology, BMC C11, 221 84 Lund, Sweden
3 Department of Physiological Sciences, The Diabetes Programme at Lund University, BMC B11, SE-211 84 Lund, Sweden
4 Section for Neuroendocrine and Cell Biology BMC F10, 221 84 Lund, Sweden
5 Section for Neuronal Survival, BMC A10, 221 84 Lund, Sweden

* To whom correspondence should be addressed.
Maria Björkqvist, E-mail: maria.bjorkqvist{at}medkem.lu.se


   Abstract

Diabetes frequently develops in Huntington's disease (HD) patients and in transgenic mouse models of HD, such as the R6/2 mouse. The underlying mechanisms have not been clarified. Elucidating the pathogenesis of diabetes in HD would improve our understanding of the molecular mechanisms involved in HD neuropathology. With this aim, we examined our colony of R6/2 mice with respect to glucose homeostasis and islet function. At week 12, corresponding to end-stage HD, R6/2 mice were hyperglycemic and hypoinsulinemic, and failed to release insulin in an intravenous glucose tolerance test. In vitro, basal and glucose-stimulated insulin secretion was markedly reduced. The abundance of nuclear huntingtin inclusions, increased dramatically over time, predominantly in {beta}-cells. {beta}-cell mass failed to increase normally with age in R6/2 mice. Hence, at week 12, {beta}-cell mass and pancreatic insulin content in R6/2 mice were 35 ± 5% and 16 ± 3% of that in wild type mice, respectively. Normally occurring replicating cells were largely absent in R6/2 islets, while no abnormal cell death could be detected. Single cell patch clamp experiments revealed unaltered electrical activity in R6/2 {beta}-cells. However, exocytosis was virtually abolished in {beta}- but not {alpha}-cells. The blunting of exocytosis could be attributed to a 96% reduction in the number of insulin-containing secretory vesicles. Thus, diabetes in R6/2 mice is caused by a combination of deficient {beta}-cell mass and disrupted exocytosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Arch NeurolHome page
N. M. Lalic, J. Maric, M. Svetel, A. Jotic, E. Stefanova, K. Lalic, N. Dragasevic, T. Milicic, L. Lukic, and V. S. Kostic
Glucose Homeostasis in Huntington Disease: Abnormalities in Insulin Sensitivity and Early-Phase Insulin Secretion
Arch Neurol, April 1, 2008; 65(4): 476 - 480.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
U. Bichelmeier, T. Schmidt, J. Hubener, J. Boy, L. Ruttiger, K. Habig, S. Poths, M. Bonin, M. Knipper, W. J. Schmidt, et al.
Nuclear Localization of Ataxin-3 Is Required for the Manifestation of Symptoms in SCA3: In Vivo Evidence
J. Neurosci., July 11, 2007; 27(28): 7418 - 7428.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Fergani, H. Oudart, J.-L. Gonzalez De Aguilar, B. Fricker, F. Rene, J.-F. Hocquette, V. Meininger, L. Dupuis, and J.-P. Loeffler
Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis
J. Lipid Res., July 1, 2007; 48(7): 1571 - 1580.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. Bjorkqvist, A. Petersen, K. Bacos, J. Isaacs, P. Norlen, J. Gil, N. Popovic, F. Sundler, G. P. Bates, S. J. Tabrizi, et al.
Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
Hum. Mol. Genet., May 15, 2006; 15(10): 1713 - 1721.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. D. Strand, A. K. Aragaki, D. Shaw, T. Bird, J. Holton, C. Turner, S. J. Tapscott, S. J. Tabrizi, A. H. Schapira, C. Kooperberg, et al.
Gene expression in Huntington's disease skeletal muscle: a potential biomarker
Hum. Mol. Genet., July 1, 2005; 14(13): 1863 - 1876.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.